Mara Goldstein
Stock Analyst at Mizuho
(2.61)
# 2,299
Out of 5,090 analysts
69
Total ratings
48.08%
Success rate
16.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $11.74 | +155.65% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.20 | +355.58% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $10.42 | -23.22% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $25.01 | +67.93% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $17.62 | +183.77% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $20.12 | +123.66% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $102.12 | -24.60% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $3.22 | +117.39% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.07 | +647.66% | 5 | Nov 20, 2023 | |
| NKTR Nektar Therapeutics | Reiterates: Neutral | $90 | $57.38 | +56.85% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $9.14 | -61.71% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.80 | +19,900.00% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $6.55 | +205.34% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $99.90 | +30.13% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $3.94 | -49.24% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.53 | +684.31% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $65.76 | -69.59% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $7.88 | +509.14% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $29.21 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.80 | +141.38% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $11.74
Upside: +155.65%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.20
Upside: +355.58%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $10.42
Upside: -23.22%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $25.01
Upside: +67.93%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $17.62
Upside: +183.77%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $20.12
Upside: +123.66%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $102.12
Upside: -24.60%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $3.22
Upside: +117.39%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.07
Upside: +647.66%
Nektar Therapeutics
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $57.38
Upside: +56.85%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $9.14
Upside: -61.71%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $1.80
Upside: +19,900.00%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $6.55
Upside: +205.34%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $99.90
Upside: +30.13%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $3.94
Upside: -49.24%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.53
Upside: +684.31%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $65.76
Upside: -69.59%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $7.88
Upside: +509.14%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $29.21
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.80
Upside: +141.38%